CHESTERFIELD, Mo., March 5, 2014 (GLOBE NEWSWIRE) -- Reliv International, Inc. (Nasdaq:RELV), a maker of nutritional supplements that promote optimal health, today reported its financial results for the fourth quarter and full year of 2013.
Reliv reported net sales of $17.4 million for the fourth quarter of 2013, compared with net sales of $16.9 million for the fourth quarter of 2012. U.S. net sales increased by 4.1 percent for the quarter compared with the same quarter in 2012. International net sales for the quarter decreased 1.5 percent compared to the prior-year quarter, but sales were buoyed by an increase in net sales of Europe of 30.3 percent.Reliv reported net income of $503,000, or $0.04 per diluted share, for the fourth quarter of 2013 compared with net income of $437,000, or $0.03 per diluted share, for the fourth quarter of 2012. Income from operations for the fourth quarter of 2013 was $888,000 compared with $611,000 in the same quarter of 2012. Full-Year Results Reliv reported net sales of $68.2 million for 2013 compared with net sales of $68.7 million in 2012. U.S. net sales were essentially flat at $53.7 million in 2013, compared to $53.8 million in 2012. Net sales in Reliv's foreign markets for 2013 decreased 2.4 percent compared with net sales for 2012. Europe remained Reliv's biggest growth market, with net sales increasing by 22.7 percent. Net income for 2013 was $777,000 compared with $1.4 million in 2012. Diluted earnings per share were $0.06 in 2013 compared with $0.11 in 2012. Net income for 2012 included a one-time after-tax gain of approximately $247,000 ($0.02 diluted EPS) resulting from a discounted balance due on a purchase agreement entered into in a previous year. "The United States reported sales gains in both the third and fourth quarters of 2013, the first year-over-year quarterly gains in the United States in more than six years at Reliv," said Robert L. Montgomery, chairman and chief executive officer of Reliv. "U.S. growth led to an increase in net sales worldwide in the third and fourth quarters, up 8.3% and 2.8% respectively, over the same periods in 2012. We believe that an updated distributor compensation plan, sustained expansion in Europe and Reliv's position as a pioneer in the field of nutritional epigenetics create a solid foundation."
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts